Bal Pharma Ltd

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about a change in the designation of a Non-Executive Non-Independent Director.

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent.

BAL PHARMA LIMITED

Bal Pharma Limited has informed the exchange about a change in the designation of its Executive Director.

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about a change in designation of a Non-Executive Non-Independent Director.

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about a change in the designation of its Executive Director.

BAL PHARMA LIMITED

BAL PHARMA LIMITED has informed BSE about a change in the designation of a Non-Executive Non-Independent Director.

BAL PHARMA LIMITED

Bal Pharma Limited has informed the BSE about a change in the designation of its Executive Director.

Bal Pharma Ltd

Bal Pharma Ltd has announced a change in designation of directors and reconstitution of statutory committees, effective from October 1, 2026, as approved by the 39th AGM on September 24, 2026.

Bal Pharma Ltd

Bal Pharma Ltd has announced the voting results and scrutinizer's report of its 39th Annual General Meeting (AGM) held on September 24, 2026. All resolutions were passed with the requisite majority.

Bal Pharma Ltd

Bal Pharma Ltd has announced the closure of its trading window from October 1, 2026, until 48 hours after the declaration of its Q2 financial results for the period ending September 30, 2026.

Bal Pharma Ltd

Bal Pharma Ltd held its 39th Annual General Meeting (AGM) on September 24, 2026, through video conferencing. The meeting was attended by 58 members, and the business mentioned in the Notice of the AGM were duly transacted. The company declared a dividend of Rs. 1.20 per equity share and re-appointed Mr. Ravindra Kumar Kothari as a Director.

Bal Pharma Ltd

Bal Pharma Ltd has fixed September 17, 2026, as the record date for payment of a final dividend of Rs. 1.20 per share. The dividend will be paid on or after September 24, 2026, to members holding equity shares as on the record date. The company will deduct tax at source (TDS) from the dividend payment, and shareholders are required to submit forms and declarations to avail of Nil or lower rate of tax deduction.

Bal Pharma Ltd

Bal Pharma Ltd has released its Annual Report 2025-26, as per SEBI Listing Regulations, along with the Notice of the 39th AGM. The report is available on the company's website.

Bal Pharma Ltd

Bal Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) on September 24, 2026, to consider various resolutions, including the re-appointment of a director and the ratification of the remuneration payable to cost auditors.

Bal Pharma Ltd

Bal Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) to be held on September 24, 2026, through video conferencing. The record date for determining the eligibility of members entitled to receive the final dividend for the financial year 2025-26 is September 17, 2026. The book closure period is from September 18 to September 24, 2026.

Bal Pharma Ltd

Bal Pharma Ltd clarifies the timeline for utilization of net proceeds of preferential issue, stating it is 18 months from allotment date, in accordance with SEBI regulations.

Bal Pharma Ltd

Bal Pharma Ltd has published unaudited financial results for the quarter ended June 30, 2026, and an IEPF notice regarding unclaimed dividends for FY 2018-19 and onwards.

Bal Pharma Ltd

Bal Pharma Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with a limited review report from the statutory auditors, M/s. SSJNB & Co, with an unmodified opinion.

Bal Pharma Ltd

Bal Pharma Ltd's board of directors met on August 12, 2026, and approved unaudited financial results for the quarter ended June 30, 2026. The board also approved changes in designations of two directors, a joint venture proposal, and the allotment of warrants to a promoter.